Regulatory Sanofi receives FDA approval for Tzield in paediatric diabetes Pharmaceutical Business ReviewThe approval expands the previous indication from those aged eight and above and was granted under a priority review process.RegulatoryMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaceutical Business Review The approval expands the previous indication from those aged eight and above and was granted under a priority review process. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: AbbVie opts for North Carolina to house $1.4bn manufacturing siteNext: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
